News Sentiment

JANX sentiment intelligence

Janux Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 16.26 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-0.9% over one week, +14.3% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Avoiding Lag: Real-Time Signals in (JANX) Movement

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -0.9% Price digesting
Trend fit Trend active 14.3% over four weeks
Fair value -40.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 37
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 10
simplywall.st 8
TradingView 6
TradingKey 4
Stock Traders Daily 2
Simply Wall Street 2
Insider Monkey 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 18
Analyst action 7
Deals and strategy 3
Balance sheet 2
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Stock Titan Direct company coverage

Director of Janux Therapeutics (JANX) receives new RSU and stock option awards

Winston Kung, a director at Janux Therapeutics (JANX), has received new equity awards comprising 5,500 restricted stock units (RSUs) and 15,500 stock options with an exercise price of $13.66 per share. The RSUs are set to vest by June 11, 2027, or the next annual stockholder meet

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Director at Janux Therapeutics (JANX) gets new RSUs and stock options

Janux Therapeutics director Vickie L. Capps was granted 5,500 restricted stock units (RSUs) and options for 15,500 shares of common stock at an exercise price of $13.66 per share. Following these awards, her direct holdings increased to 79,598 shares. The RSUs and stock options a

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 00:10
Source
Stock Titan